Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$86.72 USD

86.72
1,988,008

-0.70 (-0.80%)

Updated May 10, 2024 04:00 PM ET

After-Market: $86.72 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?

by Zacks Equity Research

The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q1 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View

by Zacks Equity Research

UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

by Zacks Equity Research

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

by Zacks Equity Research

Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.

Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?

by Zacks Equity Research

The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.

Can High Medical Costs Affect UnitedHealth's (UNH) Q1 Earnings?

by Zacks Equity Research

UnitedHealth's (UNH) first-quarter results are likely to reflect growth in premium levels and service revenues.

What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?

by Zacks Equity Research

Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.

Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q1 Earnings?

by Zacks Equity Research

UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.

Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia

by Zacks Equity Research

Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.

Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?

by Zacks Equity Research

Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of 28.36% and 12.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?

by Zacks Equity Research

Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.

Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock

by Zacks Equity Research

UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.